Moleculin Biotech, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 13, 2026, reporting a net loss of $6.493 million for the third quarter and cash of $7.287 million at period end.

Key Highlights

  • Net loss (Q3 2026): $6.493 million for the three months ended September 30, 2026, compared to $25.399 million in Q3 2025.
  • Nine-month net loss: $26.973 million for the nine months ended September 30, 2026, versus $49.112 million for the same period in 2025.
  • Cash position: $7.287 million in cash and cash equivalents as of September 30, 2026, down from $8.878 million at December 31, 2025.
  • Total operating expenses (nine months): $22.046 million, including research and development of $15.317 million and general and administrative expenses of $6.705 million.
  • Shares outstanding: 1,045,546 shares issued and outstanding at September 30, 2026, up from 159,961 at December 31, 2025; 1,061,533 shares outstanding at November 6, 2026.
  • Financing activity: Net cash provided by financing activities was $20.250 million for the nine months ended September 30, 2026, including $15.847 million from sale of common stock, pre-funded and common warrants and warrant inducement, net of costs.
  • Total stockholders' equity: $14.489 million at September 30, 2026, compared to $15.006 million at December 31, 2025.

Moleculin Biotech's Financial Position and Operations Through September 30, 2026

According to the filing, Moleculin Biotech, Inc. (NASDAQ:MBRX) reported a net loss of $6.493 million for the three months ended September 30, 2026, compared with a net loss of $25.399 million in the same quarter of 2025. The company disclosed zero revenues for both the three- and nine-month periods ended September 30, 2026 and 2025. Total operating expenses for Q3 2026 were $6.610 million, driven by research and development costs of $4.488 million and general and administrative costs of $2.114 million.

For the nine months ended September 30, 2026, the filing reported net cash used in operating activities of $21.738 million. Financing activities provided $20.250 million, which included $15.847 million from the sale of common stock, pre-funded and common warrants and warrant inducement net of costs, $2.831 million from exercise of warrants, and $1.572 million from issuance of common stock under an at-the-market equity program net of transaction costs. The company also disclosed non-cash items including equity warrants issued in relation to liability classified warrant inducements of $23.435 million and reclassification of warrant liabilities to equity upon contractual reset of exercise price of $12.675 million.

The balance sheet as of September 30, 2026 showed total assets of $20.736 million, including intangible assets of $11.148 million and cash of $7.287 million. Total liabilities were $6.247 million, including accounts payable of $3.695 million and a warrant liability of $5 thousand. The accumulated deficit stood at $232.977 million, up from $206.004 million at December 31, 2025. Net loss per common share, basic and diluted, was $(9.59) for Q3 2026, based on weighted average common shares outstanding of 757,858.

What Was Disclosed

Moleculin Biotech filed its unaudited quarterly report covering the period ended September 30, 2026, disclosing a Q3 net loss of $6.493 million, cash of $7.287 million, zero revenues, an accumulated deficit of $232.977 million, and a significant increase in shares outstanding due to warrant activity and equity issuances.